A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT ID: NCT00930059
Last Updated: 2020-11-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
191 participants
INTERVENTIONAL
2009-09-10
2010-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-04447943
PF-04447943
tablets, 25 mg every 12 hours for 12 wks
Placebo
Placebo
matching placebo tablets, every 12 hours for 12 wks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-04447943
tablets, 25 mg every 12 hours for 12 wks
Placebo
matching placebo tablets, every 12 hours for 12 wks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Good general health (such controlled conditions as Type 2 diabetes and hypertension allowed)
Exclusion Criteria
* Significant cardiovascular disease in the past 6 months
* Illness other than Alzheimer's disease that could contribute to cognitive impairment
* History of stroke or seizure disorder
55 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neurology Clinic, PC
Northport, Alabama, United States
ATP Clinical Research, Inc.
Costa Mesa, California, United States
Southwestern Research Incorporated
Glendale, California, United States
Pacific Coast Imaging (for Imaging only)
Newport Beach, California, United States
The Southwest Institute for Clinical Research, Inc.
Rancho Mirage, California, United States
Pacific Research Network (Satellite Site)
San Diego, California, United States
Pacific Research Network, Inc. (Satellite Site)
Vista, California, United States
MD Clinical
Hallandale, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Berma Research Group
Plantation, Florida, United States
Joliet Center for Clinical Research
Joliet, Illinois, United States
Fort Wayne Neurological Center
Fort Wayne, Indiana, United States
Agewell
Indianapolis, Indiana, United States
Four Rivers Clinical Research, Inc.
Paducah, Kentucky, United States
Advanced MRI
Lake Charles, Louisiana, United States
Lake Charles Clinical Trials, LLC
Lake Charles, Louisiana, United States
Neurocare, Inc.
Newton, Massachusetts, United States
Neurobehavioral Research Inc
Cedarhurst, New York, United States
Behavioral Medical Research of Staten Island
Staten Island, New York, United States
University of Pittsburgh Alzheimer's Disease Research Center
Pittsburgh, Pennsylvania, United States
Rhode Island Hospital, Alzheimer's Disease and Memory Disorders Center
Providence, Rhode Island, United States
Neurology Clinic, PC
Cordova, Tennessee, United States
Medical Arts Health Research Group
Kelowna, British Columbia, Canada
Hamilton Health Sciences
Hamilton, Ontario, Canada
Kawartha Regional Memory Clinic
Peterborough, Ontario, Canada
Neuro Rive Sud Clinic
Greenfield Park, Quebec, Canada
Diex Recherche Inc.
Sherbrooke, Quebec, Canada
Psicomed Estudios Clinicos
Antofagasta, Antofagasta, Chile
Hospital Base Valdivia
Valdivia, Los Ríos Region, Chile
Centro Doctora Lissette Duque
Providencia, RM, Chile
Psicomedica Research Group
Santiago, RM, Chile
Hospital Del Salvador
Santiago, RM, Chile
Neuroconsult
Santiago, RM, Chile
Especialidades Medicas L y S
Santiago, RM, Chile
Neuropsicologia Ltda.
La Florida, Santiago Metropolitan, Chile
Fakultni nemocnice
Hradec Králové, , Czechia
Pardubicka krajska nemocnice, a.s.
Pardubice, , Czechia
Pragtis, s.r.o.
Prague, , Czechia
Fakultni nemocnice v Motole
Prague, , Czechia
Psychiatry Trial, s.r.o.
Prague, , Czechia
Psychiatricka ambulance
Prague, , Czechia
Neurologie - EEG, s.r.o
Prague, , Czechia
Centrum neurologicke pece, s.r.o.
Rychnov nad Kněžnou, , Czechia
Psychiatricka ambulance
Strakonice, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-012179-82
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
B0401005
Identifier Type: -
Identifier Source: org_study_id